Anjo J P Veerman
Overview
Explore the profile of Anjo J P Veerman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
1328
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yolanda N, Gunawan S, Mantik M, Veerman A
Case Rep Hematol
. 2022 Nov;
2022:1185140.
PMID: 36438070
Juvenile myelomonocytic leukemia (JMML) is a rare hematopoietic malignancy in children, with an incidence of 1.2 per million children per year. At this moment, we present a case report and...
2.
Sutaryo S, Widjajanto P, Mulatsih S, Ardianto B, Pangarso A, Supriyadi E, et al.
Pediatr Blood Cancer
. 2022 Jul;
69(11):e29875.
PMID: 35856702
Background: The prognosis of childhood acute lymphoblastic leukemia (ALL) in Indonesia, a lower-middle-income country (LMIC), is lower than in high income countries (HICs). The Indonesian ALL2013 protocol resulted in too...
3.
den Hoed M, Pluijm S, Te Winkel M, de Groot-Kruseman H, Fiocco M, Hoogerbrugge P, et al.
Haematologica
. 2015 Sep;
100(12):1564-70.
PMID: 26405155
Osteonecrosis and decline of bone density are serious side effects during and after treatment of childhood acute lymphoblastic leukemia. It is unknown whether osteonecrosis and low bone density occur together...
4.
Gunawan S, Arnoldussen M, Gordijn M, Sitaresmi M, van de Ven P, Ten Broeke C, et al.
Pediatr Blood Cancer
. 2015 Aug;
63(1):118-23.
PMID: 26274831
Background: Use of complementary and alternative medicine (CAM) is common among patients with childhood cancer. Health-care providers (HCP) should address this need properly. Geographical and cultural differences seem likely. This...
5.
den Hoed M, Pluijm S, de Groot-Kruseman H, Te Winkel M, Fiocco M, van den Akker E, et al.
Haematologica
. 2014 Oct;
100(1):62-9.
PMID: 25304613
Body mass index and change in body mass index during treatment may influence treatment outcome of pediatric patients with acute lymphoblastic leukemia. However, previous studies in pediatric acute lymphoblastic leukemia...
6.
Te Winkel M, Pieters R, Hop W, Roos J, Bokkerink J, Leeuw J, et al.
Bone
. 2013 Nov;
59:223-8.
PMID: 24287213
Purpose: To elucidate incidence and risk factors of bone mineral density and fracture risk in children with Acute Lymphoblastic Leukemia (ALL). Methods: Prospectively, cumulative fracture incidence, calculated from diagnosis until...
7.
Schuitema I, Deprez S, Van Hecke W, Daams M, Uyttebroeck A, Sunaert S, et al.
J Clin Oncol
. 2013 Aug;
31(27):3378-88.
PMID: 23960182
Purpose: CNS-directed chemotherapy (CT) and cranial radiotherapy (CRT) for childhood acute lymphoblastic leukemia or lymphoma have various neurotoxic properties. This study aimed to assess their impact on the maturing brain...
8.
Sitaresmi M, Mostert S, Gundy C, Ismail D, Veerman A
Pediatr Blood Cancer
. 2013 Jun;
60(10):1593-7.
PMID: 23733528
Background: Event-free survival of pediatric patients with acute lymphoblastic leukemia (ALL) in Yogyakarta, Indonesia was low (20%). The aim of the study was to evaluate the effectiveness of using a...
9.
Widjajanto P, Sumadiono S, Purwanto I, Sutaryo S, Veerman A
J Pediatr Hematol Oncol
. 2013 Feb;
35(8):597-602.
PMID: 23389497
We conducted a randomized trial to compare the influence of 3 additional doses of L-asparaginase on clinical outcome of newly diagnosed childhood acute lymphoblastic leukemia (ALL). Patients were treated using...
10.
Supriyadi E, Veerman A, Sutaryo , Purwanto I, Vd Ven P, Cloos J
J Oncol
. 2012 Dec;
2012:135186.
PMID: 23227046
The frequency of acute lymphoblastic leukemia (ALL) patients expressing myeloid antigens on their ALL cells varies between 5 and 36% in several different studies. The clinical relevance of myeloid antigen...